


## PHARMACEUTICAL 2017

## Orexigen Therapeutics Inc. Rank 39 of 313





## PHARMACEUTICAL 2017



## Orexigen Therapeutics Inc. Rank 39 of 313

The relative strengths and weaknesses of Orexigen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orexigen Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 190% points. The greatest weakness of Orexigen Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 157% points.

The company's Economic Capital Ratio, given in the ranking table, is 93%, being 509% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	224,461
Cost of Goods Sold	0
Intangible Assets	76,061
Liabilities, Current	65,360
Liabilities, Non-Current	0
Other Assets	3,023
Other Compr. Net Income	3,795
Other Expenses	-65,794
Other Liabilities	0
Other Net Income	32,579
Property and Equipment	1,044
Research and Development	38,023
Revenues	33,709
Selling, General and Administrative Expense	118,583

Output Variable	Value in 1000 USD
Assets	304,589
Liabilities	65,360
Expenses	90,812
Stockholders Equity	239,229
Net Income	-24,524
Comprehensive Net Income	-22,626
Economic Capital Ratio	93%